In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Orthofix (NASDAQ: OFIX), with a price target of $60. The company’s shares opened today at $55.14.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 31.7% and a 74.6% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Orthofix with a $65 average price target.
See today’s analyst top recommended stocks >>
Orthofix’s market cap is currently $1.02B and has a P/E ratio of 90.48. The company has a Price to Book ratio of 3.19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Orthofix Medical, Inc. engages in the research, development, and market of orthopedic solutions. It operates through the following business segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The BioStim segment produces and sells devices for bone fusion enhancement in cervical and lumbar spine through the pulsed electromagnetic technology.
